Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$49.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

La Jolla Pharmaceutical Co reports positive, top-line results from phase 2 clinical trial of gcs-100 in chronic kidney disease


Monday, 10 Mar 2014 04:15pm EDT 

La Jolla Pharmaceutical Co:Announced positive top-line results from its randomized, placebo-controlled Phase 2 trial of GCS-100 in chronic kidney disease (CKD).Trial met its primary efficacy endpoint of a statistically significant improvement in kidney function.Specifically, a dose of 1.5 mg/m(2)led to a statistically significant (p=0.045) increase in estimated glomerular filtration rate (eGFR) compared to placebo between baseline and end of treatment. At the 30 mg/m(2)dose, there was no statistically significant difference.Key secondary endpoints were also met, and the effect on circulating galectin-3 levels was consistent with the effect on eGFR. 

Related Company News

Company Quote

22.19
 --
27 Jan 2015